Chief Strategy Officer

Immunomedics was a biotechnology company focused on the development of antibody-drug conjugates for the treatment of cancer. In 2020, the company was acquired by Gilead Sciences.

Immunomedics was founded in July 1982 by David M. Goldenberg.

Michael Pehl was named CEO in December 2017 but left due to personal reasons in February 2019. At that time, Dr. Behzad Aghazadeh was named Executive Chairman.

In October 2020, Gilead Sciences acquired the company.[1] In March 2022, Gilead announced the closing of the former Immunomedics facility in Morris Plains.